CHEMO-PHARMA LABORATORIES LTD.

NSE : NABSE : 506365ISIN CODE : INE320M01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE82.50-0.4 (-0.48 %)
PREV CLOSE ( ) 82.90
OPEN PRICE ( ) 82.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 316
TODAY'S LOW / HIGH ( )82.50 82.90
52 WK LOW / HIGH ( ) 27.1787
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2016
Profit Before Tax-13.47
Adjustment-4.87
Changes In working Capital-1.79
Cash Flow after changes in Working Capital-20.12
Cash Flow from Operating Activities-20.92
Cash Flow from Investing Activities21.52
Cash Flow from Financing ActivitiesNA
Net Cash Inflow / Outflow0.61
Opening Cash & Cash Equivalents3.78
Cash & Cash Equivalent on Amalgamation / Take over / MergerNA
Cash & Cash Equivalent of Subsidiaries under liquidationsNA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNA
Effect of Foreign Exchange FluctuationsNA
Closing Cash & Cash Equivalent4.39

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.